The price of Oncology Institute Inc (NASDAQ:TOI) shares last traded on Wall Street fell -26.56% to $0.13.
TOI stock price is now -55.47% away from the 50-day moving average and -82.89% away from the 200-day moving average. The market capitalization of the company currently stands at $9.99M.
On September 14, 2022, Guggenheim recently initiated its ‘Buy’ rating on the stock quoting a target price of $7, while ‘Jefferies’ rates the stock as ‘Buy’
In other news, Havencrest Healthcare Partners, 10% Owner sold 8,637 shares of the company’s stock on Jan 29 ’24. The stock was sold for $18,310 at an average price of $2.12. Upon completion of the transaction, the 10% Owner now directly owns 0 shares in the company, valued at $0.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 24 ’24, 10% Owner Havencrest Healthcare Partners sold 24,915 shares of the business’s stock. A total of $57,304 was realized by selling the stock at an average price of $2.30. This leaves the insider owning 27,498 shares of the company worth $3574.74. A total of 51.30% of the company’s stock is owned by insiders.
During the past 12 months, Oncology Institute Inc has had a low of $0.17 and a high of $2.50. As of last week, the company has a debt-to-equity ratio of 7.94, a current ratio of 2.49, and a quick ratio of 2.27. The fifty day moving average price for TOI is $0.30006 and a two-hundred day moving average price translates $0.7826 for the stock.
The latest earnings results from Oncology Institute Inc (NASDAQ: TOI) was released for 2024-06-30. The net profit margin was -15.17% and return on equity was -131.66% for TOI. The company reported revenue of $99.9 million for the quarter, compared to $82.03 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 21.78 percent.
